🔴 ABIVAX is trading 4.69% down today after first-half net loss widened to €165.9 million

ABIVAX is trading at €86.40, down 4.69% now, after first-half results showed a €165.9 million net loss, versus €100.8 million a year earlier.

• September 21, 2026 results also showed substantially higher operating expenses, including R&D and G&A spending.
• September 22 analyst price-target reductions reinforced the decline.
• Management highlighted cash runway into Q4 2029 and plans to file for obefazimod by year-end.